Sagittarius Life Science Corp.

New drug research and development, nutrition and health care products, skin care products.
From the nature of the secret ~ Superfood
Sagittarius Life Science research combined with high-tech precision technology, extract high-performance high-purity material.
With patented process safety certification, combined with medical knowledge, developed with a specific effect of health care products.
To create a market potential and product strength of the product, accurate nutrition back to health, win to the beautiful wonderful life.

San Paul Biotechnology Corp., Ltd.

1. S.CANAAN Agaricus Blazei Murrill 

2. IMMUNIFIX Supplement for Pets

Sanshin Nutrition Technology Co., Ltd.

Nowadays, pharmaceuticals companies take neuraminidase inhibitors as a platform for developing influenza drugs. Antiviral drugs acts as viral neuraminidase inhibitors, which stops the virus replication. However, scientists find some problems that antiviral drugs are difficult to solve the flu disease. The most serious one is that, to now, antiviral drugs couldn't act against all types of influenza neuraminidases. Consequently, some viruses won't be blocked, which stands for the drug resistance. These residual viruses will keep replicating. In the end, influenza viruses will develop drug resistance.
The manner, we use, to prevent and treat the influenza disease is by inducing mucosal immunity that leads to the generation of the immunoglobulin A, which is cooperated with the humoral immunity IgG. From the laboratory experiment, the manner shows the positive result against the H1N1 virus. Besides, it has been successfully applied to the feeding of poultry against the bird flu. Now, it has been applied to preventing the flu. If commonly used all over the world, it will terminate the loss by influenza diseases.

Sartonets Taiwan., Ltd

contract services & manufacturing equipment for biopharmaceutical,
lab/ pipeline/ facility design & basic equipment

SciVision Biotech Inc.

1. Hyaluronic Acid-based Dermal Filler
2. Hyaluronic Acid-based Synovial Fluid Supplement
3. Hyaluronic Acid-based Adhesion Barrier
4. Hyaluronic Acid-based Intravesical Instillation

Senhwa Biosciences, Inc.

Senhwa Biosciences, Inc. (6492:TT) was established in 2012 and aims to transform the Senhwa Biosciences, Inc. (6492:TT) established in 2012, is a clinical stage drug development company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer. Developing first-in-class small molecule drugs used in cancer treatments is Senhwa’s corporate mission. Headquartered in Taiwan, but with a vital operational base in San Diego, California, Senhwa has a strong Management Team with proven track records in developing new drugs and targeted agents. Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global investigators and service providers. Clinical trials are ongoing or planned for US, Australia, Korea, Canada and Taiwan. Currently Senhwa has multiple clinical projects in its pipeline with 106 granted patents, worldwide with 14 additional patents pending.
Current development focuses on two main drug candidates CX-5461 and CX-4945 with multiple indications. CX-5461 is G4 (G-quadruplex) stabilizer, targets tumors with BRCA1/2 mutations or HR deficiency (HRD). CX-5461 was chosen as the 2015 Canada SU2C (Stand up to Cancer) Dream Team Drug, the only and the first Dream Team Drug in Asia. Another innovative product CX-4945 is Casein Kinase II (CK2) inhibitor. When CX-4945 is combined with DNA damaging agents i.e. gemcitabine and cisplatin, the combination has shown to have synergistic effect in treating targeted cancer. CX-4945 was granted Orphan Drug designation by the US FDA for the treatment of Cholangiocarcinoma in Dec., 2016.
On April 24, 2017, Senhwa completed IPO and was approved to list on the Taipei Exchange mainboard. As a value-added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through to clinical Proof-of-Concept.

Shin Kong Wu Ho-Su Memorial Hospital

1. Hospital: Interventional Treatment, Health Management Center
2. SHIN KONG LIFE
3. Care U-Cloud Home Care Service

Shire Biotech Taiwan Ltd.

Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal/Internal Medicine/Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our Story
Shire was founded in 1986 in the UK. Shire's Asia Pacific headquarters in Singapore is the regional hub to 10 locations across Australia/New Zealand, China, Korea, Taiwan/Hong Kong and South East Asia. Singapore is also home to Shire's first biologics manufacturing site in Asia that officially opened on 7 August 2014. The Woodlands manufacturing facility is one of Shire's 17 world-class manufacturing sites around the world, and the only facility outside the U.S. and Europe.
Today we have more than 22,000 employees worldwide and offices in over 60 countries. Our products are marketed in more than 100 countries, enabling us to help improve the lives of people around the world whose health is impacted by rare and other highly specialized conditions.

Show Chwan Memorial Hospital

1. IRCAD-Taiwan Minimally Invasive Surgery Education and RD Center
2. Medical Device Innovation Incubation Platform
3. MonoStereo, Endoscopic 3D Vision System
4. Augmented Reality and Image Guided Navigation Technology
5. Cloud, Mobile and IOT in Hospital
6. Show Chwan Healthcare System and Service

Silicon Based Molecular Sensoring Technology Co., Ltd.

Founded in 2014, SBMS is dedicated to developing a biomedical platform that facilitates the non-invasive and real-time detection of minimum pathogens for patients. Our core team is composed of professionals from the Quantum Electronic Laboratory at Academia Sinica with exclusive expertise in semiconductor chip design/fabrication, probe molecules modification and automation bio-sensor system integration. In addition, our researches were published by SCI journal and earned relevant patents. With widely-recognized performance, SBMS was honored to win the 13th National Innovation Award in 2016.Going forward, SBMS will leverage this top-notch platform to provide high sensitive, accurate and user-friendly products in the biomedical detection market worldwide.